These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28792913)

  • 1. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
    Apostolakis S; Kypraiou AM
    Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron and Parkinson's disease: chelators to the rescue?
    Levenson CW
    Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
    Gassen M; Youdim MB
    Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targets and therapeutic interventions for iron induced neurodegeneration.
    Bagwe-Parab S; Kaur G
    Brain Res Bull; 2020 Mar; 156():1-9. PubMed ID: 31866454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An attempt to elucidate the role of iron and zinc ions in development of Alzheimer's and Parkinson's diseases.
    Wojtunik-Kulesza K; Oniszczuk A; Waksmundzka-Hajnos M
    Biomed Pharmacother; 2019 Mar; 111():1277-1289. PubMed ID: 30841441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does any drug to treat cancer target mTOR and iron hemostasis in neurodegenerative disorders?
    Jodeiri Farshbaf M; Ghaedi K
    Biometals; 2017 Feb; 30(1):1-16. PubMed ID: 27853903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cationic albumin-conjugated chelating agent as a novel brain drug delivery system in neurodegeneration.
    Kamalinia G; Khodagholi F; Shaerzadeh F; Tavssolian F; Chaharband F; Atyabi F; Sharifzadeh M; Amini M; Dinarvand R
    Chem Biol Drug Des; 2015 Nov; 86(5):1203-14. PubMed ID: 25976552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects.
    Tian S; Wang B; Ding Y; Zhang Y; Yu P; Chang YZ; Gao G
    Biomed Pharmacother; 2024 Oct; 179():117419. PubMed ID: 39245001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is early-life iron exposure critical in neurodegeneration?
    Hare DJ; Arora M; Jenkins NL; Finkelstein DI; Doble PA; Bush AI
    Nat Rev Neurol; 2015 Sep; 11(9):536-44. PubMed ID: 26100754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.